Five things for pharma marketers to know:
- The Food and Drug Administration lifted the clinical hold on a Phase 1 study for PepGen’s DM1 drug candidate.
- Karuna Therapeutics indicated it will more than double its workforce if its novel drug for schizophrenia is approved.
- Peter Marks, director of the Center for Biologics Evaluation and Research at the FDA, discussed his ambitions for an Operation Warp Speed targeted at rare diseases.
- OptimizeRx announced it is buying Medicx Health for $95 million and guided for higher revenue for the third quarter.
- Israeli biotech startup Mana.bio had been planning to launch its programmable drug treatment solution for months and decided to forge ahead in spite of the attacks that happened this past weekend in the country.
